Find trials
Consejos para buscar

THA Lumbar Plexus Verses Periarticular

Overview

Información sobre este estudio

Total hip arthroplasty is a one of the most commonly performed surgical procedures with increasing numbers anticipated over the next several decades. Differences in the analgesia outcomes between these three intervention groups would provide for an evidenced-based clinical pathway that will emerge as a result of this study.

Hypothesis:

Patients undergoing total hip arthroplasty within a clinical pathway utilizing preemptive low-dose opioid and non-opioid medications for multimodal analgesia randomized to peripheral nerve blockade will report less pain with movement on an NRS scale POD #1 compared to randomization to periarticular injection with ropivacaine mixture or periarticular injection with liposomal bupivacaine (Exparel®).

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Inclusion:

  1. Adult patients with an American Society of Anesthesiologists (ASA) physiological status I-III
  2. Patients presenting for unilateral primary total hip arthroplasty.
  3. Patients 18 years of age and older

Exclusion:

  1. Chronic pain syndromes such as fibromyalgia or complex regional pain syndrome
  2. History of long term use of daily opioids (>1 months) with OME >5mg/day.
  3. Body mass index (BMI) > 40 kg/m2
  4. Allergies to medications used in this study such as: fentanyl, hydromorphone, ketorolac, ibuprofen, acetaminophen, local anesthetics, oxycodone, tramadol, ondansetron, droperidol, dexamethasone, celecoxib and OxyContin.

  5. Major systemic medical problems such as:

    1. severe renal disorder defined as glomerular filtration rate (GFR) <50 units/m2
    2. cardiovascular disorders defined as CHF NYHA class III-IV
    3. severe hepatic disorder defined as current or past diagnosis of acute/subacute necrosis of liver, acute hepatic failure, chronic liver disease, cirrhosis (primary biliary cirrhosis), fatty liver, chronic hepatitis/toxic hepatitis, liver abscess, hepatic coma, hepatorenal syndrome, other disorders of liver
  6. Impaired cognitive function or inability to understand the study protocol
  7. Contraindication to a regional anesthesia technique (e.g., preexisting neuropathy in the operative extremity, coagulopathy [platelets < 100,000, INR >1.5], refusal, etc.).
  8. Previous contralateral hip replacement managed with regional or periarticular injection
  9. Unable to follow-up at the 3 month interval at Mayo Clinic in Rochester, MN
  10. Pregnancy or breastfeeding (women of child-bearing potential will require a negative pregnancy test

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus

Rochester, Minn.

Investigador principal de Mayo Clinic

Rebecca Johnson, M.D.

Cerrado para la inscripción

More information

Publicaciones

Publications are currently not available

Otros temas en investigación

.
CLS-20142715

Mayo Clinic Footer